Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I AEB071 in metastatic uveal melanoma
NL-OMON41444Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sotrastaurin in intraocular melanoma (2 arms), sponsored by Novartis. Primary endpoints: Dose-limiting toxicities and Safety and tolerability. Started Dec 2011; status: active, not recruiting.
02
Drugs
sotrastaurin
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on NL-OMON41444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41444.